The Pharmaceutical Journal
Vol 280 No 7487 p110
2 February 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Rosiglitazone warning

A warning that rosiglitazone is not recommended for patients with ischaemic heart disease or peripheral arterial disease should be included in the drug’s product information, the European Medicines Agency has announced.
(PDF 40K)

Also recommended is a new contraindication stating that rosiglitazone must not be used in patients with an acute coronary syndrome, such as angina or some types of myocardial infarction.